2016 American Transplant Congress
Incidence, Risk Factors, and Outcomes of Delayed Graft Function in Deceased Donor Kidney Transplantation in a Brazilian Center.
Background. A high incidence of delayed graft function (DGF), after deceased donor kidney transplantation, occurs in Brazil and the reasons for such finding have not…2016 American Transplant Congress
Outcomes in Black vs Non-Black Patients Administered Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT.
Studies consistently show worse outcomes for black vs non-black kidney transplant recipients. At 7 yrs post-transplant in BENEFIT, bela was associated with superior graft survival…2016 American Transplant Congress
Chemoprevention of Cutaneous Squamous Cell Carcinoma in Renal Transplant Recipients: A Case-Controlled Analysis.
Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom.
Organ transplant recipients are up to 200 times more likely to develop cutaneous squamous cell carcinoma (SCC) than age-matched general populations. Systemic retinoids, such as…2016 American Transplant Congress
Impact of BKV Subtype Distribution on BKV Nephropathy, Viremia, and Renal Outcome in Patients After Renal Transplantation.
Factors determining the course of BK viral (BKV) infection remain uncertain. We studied the role of BKV subtype distribution in BKV-infected patients after renal transplantation.-We…2016 American Transplant Congress
Long Term Safety of Intravenous Ketorolac Use After Donor Nephrectomy.
Background: The benefit and short-term safety have been established in previous studies; however, the risk of bleeding and long-term renal impairment in patients undergoing donor…2016 American Transplant Congress
AT1R Antibodies at 1-Year Negatively Impact 5-Year Native Renal Function in Liver Transplant Recipients.
Angiotensin II Type-1 Receptor (AT1R) antibodies have been associated with pulmonary hypertension, renal allograft loss, and fibrosis progression in liver allograft recipients especially if combined…2015 American Transplant Congress
Belatacept-Treated Patients Had Better Graft Survival at 7-Years Post-Transplant Compared With Cyclosporine-Treated Patients: Final Results from BENEFIT
Background: At 3yrs, improvement in renal function was seen in kidney transplant recipients treated with belatacept (bela) vs cyclosporine (CsA) in BENEFIT. Here we report…2015 American Transplant Congress
mTOR-Based CNI Minimization Vs Withdrawal in African American Kidney Transplant Recipients
The purpose of this study was to compare mTOR-based CNI withdrawal vs. minimization in African American (AA) kidney transplant (KTx) recipients.METHODS: This was a single-center,…2015 American Transplant Congress
Impact of Proton Pomp Inhibitors on Hypomagnesemia and Arterial Stiffness in Renal Transplant Recipients
Purpose: Hypomagnesemia predicts cardiovascular morbidity and mortality in the general population and accelerated loss of kidney function in renal transplant recipients (RTRs). Proton pomp inhibitors…2015 American Transplant Congress
Month 48 Follow-Up Results of HERAKLES Trial on Three Different Treatment Regimen and Switching Off Behaviour in De Novo Renal Transplant Patients
1Herakles Study Group, Germany; 2Novartis, Pharma, Germany; 3Herakles Study Group, Switzerland.
Aim: To compare switching off 3 different immunosuppressive (IS) regimen 4years after renal transplantation (Tx).Methods: 802 patients (pts) were included in this prospective, open-label, randomized,…
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- 27
- Next Page »